MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs

MaaT Pharma has announced a €37.5 million financing deal with the European Investment Bank (EIB). This funding will support the development of its late-stage hemato-oncology assets, particularly Xervyteg® and MaaT033. Xervyteg® is under review by the European Medicines Agency for a potential approval, while MaaT033 is in Phase 2b clinical trial.

This tranche-based financing is part of MaaT Pharma's strategy to advance its microbiome-based therapies, aiming to improve cancer patient survival. The deal follows a thorough due diligence process by EIB, confirming MaaT Pharma's innovative approaches and solid operational foundation.

The €37.5 million loan is structured into four tranches, with redemption periods of up to eight years and interest set at 7%. Additionally, warrants will be issued to EIB, exercisable following the maturity of Tranche A.